HDA Appoints VP of Regulatory Affairs
Organization hires Kala Shankle, who joins the team with supply chain security and drug pricing experience.
The Healthcare Distribution Alliance (HDA) has brought on Kala Shankle as VP of regulatory affairs. In this position, she will direct regulatory activities and priorities on behalf of HDA’s 35 healthcare distributor members. Shankle will report to HDA Executive VP of government affairs, Patrick Kelly.
In her most recent role, she worked as an attorney for Epstein, Becker and Green, where she counseled pharmaceutical supply chain stakeholders on regulatory and compliance matters, including supply chain security, drug pricing, Drug Supply Chain Security Act (DSCSA) implementation, and the Inflation Reduction Act (IRA). Previously, Shankle provided legal counsel, developed policy solutions and led regulatory engagement for the National Association of Chain Drug Stores (NACDS) and the National Community Pharmacists Association (NCPA).
“Kala brings deep legal and pharmaceutical supply chain experience, which will be beneficial to our association when interfacing with regulatory agencies,” notes Kelly. “As HDA’s healthcare distributor members navigate the final stages of DSCSA implementation and additional regulatory issues in the years to come, Kala will provide distributors with critical guidance to enable them to support a safe and effective pharmaceutical supply chain in the US.”
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.
